Ubs Global Asset Management Americas »

Arrowhead Pharmaceuticals In Note 1/1 shares owned by Ubs Global Asset Management Americas

Quarter-by-quarter ownership of Arrowhead Pharmaceuticals In Note 1/1 shares owned by Ubs Global Asset Management Americas from 13F filings

Historical chart of Ubs Global Asset Management Americas investment in Arrowhead Pharmaceuticals In Note 1/1

Tip: Access up to 7 years of quarterly data

All positions including Arrowhead Pharmaceuticals In Note 1/1 held by Ubs Global Asset Management Americas consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrowhead Pharmaceuticals In Note 1/1 by Ubs Global Asset Management Americas

Quarter filed Position value Share count Share price at filing
2026-06-30 $35M 29M 1.19

More positions owned by Ubs Global Asset Management Americas

NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
Micron Technology (MU)
Advanced Micro Devices (AMD)
Alphabet Cap Stk Cl C (GOOG)
Eli Lilly & Co. (LLY)
Tesla Motors (TSLA)
Meta Platforms Cl A (META)
Applied Materials (AMAT)
Intel Corporation (INTC)
JPMorgan Chase & Co. (JPM)

View all positions for Ubs Global Asset Management Americas

Top funds holding Arrowhead Pharmaceuticals In Note 1/1

Deerfield Management Company
Camden Asset Management
LMR Partners
Linden Advisors
Ubs Global Asset Management Americas
Readystate Asset Management
Lazard Asset Management
Calamos Advisors
MacKay Shields
DeepCurrents Investment Group
Context Capital Management
Advent Capital Management
State Street Corporation
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Oaktree Capital Management

View all funds holding Arrowhead Pharmaceuticals In Note 1/1